139 related articles for article (PubMed ID: 38613589)
1. Subcellular expression of MTA1, HIF1A and p53 in primary tumor predicts aggressive triple negative breast cancers: a meta-analysis based study.
Sharaf SS; Jaganath Krishna KM; Lekshmi A; Sujathan
J Mol Histol; 2024 Jun; 55(3):303-315. PubMed ID: 38613589
[TBL] [Abstract][Full Text] [Related]
2. Association of p53 expression with poor prognosis in patients with triple-negative breast invasive ductal carcinoma.
Li JP; Zhang XM; Zhang Z; Zheng LH; Jindal S; Liu YJ
Medicine (Baltimore); 2019 May; 98(18):e15449. PubMed ID: 31045815
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of survivin and EGFR protein expression in triple-negative breast cancer (TNBC) patients.
Zhang M; Zhang X; Zhao S; Wang Y; Di W; Zhao G; Yang M; Zhang Q
Target Oncol; 2014 Dec; 9(4):349-57. PubMed ID: 24233638
[TBL] [Abstract][Full Text] [Related]
4. Stratification of Prognosis of Triple-Negative Breast Cancer Patients Using Combinatorial Biomarkers.
Yue Y; Astvatsaturyan K; Cui X; Zhang X; Fraass B; Bose S
PLoS One; 2016; 11(3):e0149661. PubMed ID: 26930401
[TBL] [Abstract][Full Text] [Related]
5. Carboxypeptidase A4 negatively correlates with p53 expression and regulates the stemness of breast cancer cells.
Wang Y; Xie Y; Niu Y; Song P; Liu Y; Burnett J; Yang Z; Sun D; Ran Y; Li Y; Sun L
Int J Med Sci; 2021; 18(8):1753-1759. PubMed ID: 33746592
[No Abstract] [Full Text] [Related]
6. Prognostic significance of cyclin D1, β-catenin, and MTA1 in patients with invasive ductal carcinoma of the breast.
Cheng CW; Liu YF; Yu JC; Wang HW; Ding SL; Hsiung CN; Hsu HM; Shieh JC; Wu PE; Shen CY
Ann Surg Oncol; 2012 Dec; 19(13):4129-39. PubMed ID: 22864797
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer.
Maeda T; Nakanishi Y; Hirotani Y; Fuchinoue F; Enomoto K; Sakurai K; Amano S; Nemoto N
Med Mol Morphol; 2016 Mar; 49(1):11-21. PubMed ID: 26009308
[TBL] [Abstract][Full Text] [Related]
8. Androgen receptor and metastasis-associated protein-1 are frequently expressed in estrogen receptor negative/HER2 positive breast cancer.
Zhao L; Niu F; Shen H; Liu X; Chen L; Niu Y
Virchows Arch; 2016 Jun; 468(6):687-96. PubMed ID: 27026268
[TBL] [Abstract][Full Text] [Related]
9. P53 and Ki-67 as prognostic markers in triple-negative breast cancer patients.
Pan Y; Yuan Y; Liu G; Wei Y
PLoS One; 2017; 12(2):e0172324. PubMed ID: 28235003
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer: a systematic review and meta-analysis.
Gao G; Wang Z; Qu X; Zhang Z
BMC Cancer; 2020 Mar; 20(1):179. PubMed ID: 32131780
[TBL] [Abstract][Full Text] [Related]
11. The expressions of NEDD9 and E-cadherin correlate with metastasis and poor prognosis in triple-negative breast cancer patients.
Li P; Sun T; Yuan Q; Pan G; Zhang J; Sun D
Onco Targets Ther; 2016; 9():5751-5759. PubMed ID: 27703373
[TBL] [Abstract][Full Text] [Related]
12.
Uzelac B; Krivokuca A; Susnjar S; Milovanovic Z; Supic G
Genet Test Mol Biomarkers; 2021 Mar; 25(3):227-235. PubMed ID: 33734898
[No Abstract] [Full Text] [Related]
13. Mutant p53 and Twist1 Co-Expression Predicts Poor Prognosis and Is an Independent Prognostic Factor in Breast Cancer.
Zhang YQ; Zhang F; Zeng YZ; Chen M; Huang WH; Wu JD; Chen WL; Gao WL; Bai JW; Yang RQ; Zeng HC; Wei XL; Zhang GJ
Front Oncol; 2021; 11():628814. PubMed ID: 34249678
[TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of EGFR and cytokeratin 5/6 immunohistochemical expression in triple-negative breast cancer.
Abdelrahman AE; Rashed HE; Abdelgawad M; Abdelhamid MI
Ann Diagn Pathol; 2017 Jun; 28():43-53. PubMed ID: 28648939
[TBL] [Abstract][Full Text] [Related]
15. Active behavior of triple-negative breast cancer with adipose tissue invasion: a single center and retrospective review.
Yamaguchi J; Moriuchi H; Ueda T; Kawashita Y; Hazeyama T; Tateishi M; Aoki S; Uchihashi K; Nakamura M
BMC Cancer; 2021 Apr; 21(1):434. PubMed ID: 33879104
[TBL] [Abstract][Full Text] [Related]
16. High Densities of Tumor-Associated Plasma Cells Predict Improved Prognosis in Triple Negative Breast Cancer.
Yeong J; Lim JCT; Lee B; Li H; Chia N; Ong CCH; Lye WK; Putti TC; Dent R; Lim E; Thike AA; Tan PH; Iqbal J
Front Immunol; 2018; 9():1209. PubMed ID: 29899747
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of Triple-Negative Breast Cancers (TNBC) Compared with Non-TNBC: Does the Survival Vary for All Stages?
Agarwal G; Nanda G; Lal P; Mishra A; Agarwal A; Agrawal V; Krishnani N
World J Surg; 2016 Jun; 40(6):1362-72. PubMed ID: 26842691
[TBL] [Abstract][Full Text] [Related]
18. Metastasis-associated protein 1 as a new prognostic marker for solid tumors: a meta-analysis of cohort studies.
Luo H; Li H; Yao N; Hu L; He T
Tumour Biol; 2014 Jun; 35(6):5823-32. PubMed ID: 24599674
[TBL] [Abstract][Full Text] [Related]
19. Gene expression in triple-negative breast cancer in relation to survival.
Wang S; Beeghly-Fadiel A; Cai Q; Cai H; Guo X; Shi L; Wu J; Ye F; Qiu Q; Zheng Y; Zheng W; Bao PP; Shu XO
Breast Cancer Res Treat; 2018 Aug; 171(1):199-207. PubMed ID: 29748761
[TBL] [Abstract][Full Text] [Related]
20. Molecular biomarkers for prediction of response to treatment and survival in triple negative breast cancer patients from Egypt.
Bahnassy A; Mohanad M; Ismail MF; Shaarawy S; El-Bastawisy A; Zekri AR
Exp Mol Pathol; 2015 Oct; 99(2):303-11. PubMed ID: 26232605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
